資源描述：
《槲寄生中的化學成分及其抗腫瘤活性(ⅰ)》由會員上傳分享，免費在線閱讀，更多相關內容在教育資源-天天文庫。
1、萬方數據天然產物研究與開發(fā)肋tProd腸Dev2009。21：44l444，452文章編號：1001-688012009}03-0441-05槲寄生中的化學成分及其抗腫瘤活性【I)陳柏年，李建寬，楊宮娥+，李青山山西醫(yī)科大學藥學院中藥學教研室，太原030001摘要：從槲寄生75％乙醇提取物中分離得到4個化合物，應用波譜學方法鑒定它們的結構為尼克酰胺(1)，乙酰胺(2)，齊墩果酸(3)，口．香樹脂醇乙酸酯(4)。其中，化合物1和2為首次從槲寄生屬植物中分離得到。采用MTr法對化合物1—4進行體外抗腫瘤活性研究，結果顯示化合物1、2和4對H0-8910人卵巢漿液性腺癌、SMMC7721人肝癌、T
2、24人膀胱癌、HepG2人肝癌和SHG人神經膠質瘤細胞系沒有細胞毒活性，化合物3則對這五種腫瘤細胞系有顯著的抑制作用。關鍵詞：槲寄生；尼克酰胺；齊墩果酸；抗腫瘤；MTT法中圖分類號：Q58；R284．2文獻標識碼：AChemicalConstituentsfromViscumcoloratum(Kom．)NakaiandTheirAntitumorActivities(I)CHENBai—nian，LIJian—kuan，YANGGuan—e+，LIQing-shanDepartmentofTraditionalChineseMedicine，SchoolofPharmaceuticalSc
3、iences，ShanxiMedicalUniversity，Taiyuan030001，ChinaAbstract：Fourchemicalconstituentswereisolatedfromthe75％ethanolextractofViscumcoloratum(Kom．)Nakaiandtheirstructureswereidentified鵲nicotinamide(1)，aeetamide(2)，oleanolicacid(3)，肛鋤徊nacetate(4)byspectralmethods．Theantitumoractivitiesofcompounds14werest
4、udiedbyMTTmethod訊vitro．Compounds1，2and4showednocytotoxicactivitiesagainstHO-8910humanovary昵rouBadenoearcinoma．SMMC7721humanhepatoma；T24humanbladdercancer；HepG2humanhepatomaandSHGhumangliomacelllines，andcompound3showedsignificantinhibitoryactivitiesagainstthosefivehumantumorcelllines．．Keywords：V／scu
5、mcoloratura(Kom．)Nakai；nicofinamide；oleanolicacid；antitumor；M1-I'IntroductionThemistletoeisaperennialsemiparasiticdwarfshrub，whichcontainsaboutmorethan30species，ofwhich1growinChina?！В甋ince1920s，themistletoehasbeenusedforthetreatmentofcancers，suchasbreastCallC—er，gastriccancer，rectalcancer，etc[劉．Wit
6、hthedevel．opmentofcomplementaryoralternativemedicine(CAM)aroundtheworld，thepreparationsmadefrommistletoealebecomingmorepopular．Itisestimatedthattheyearlyexpenditureforthesepreparationsis0．ver$30millioninGermanyalonewithanannualin—ReceivedOctober15，2007；AcceptedJanuary16，2008FoundationItem：Thisworkw
7、assupportedbytheNationalNaturalSci—enceFoundationofChina(30672621)。ShamdProvineialNaturalSci-enceFoundation(20060l1099)andShanx／MedicalUniversity2007StudentInnovationFund．·CorrespondingauthorTel：86-351-4690
